Last reviewed · How we verify
Anti-IL2R AB
Anti-IL2R antibody
Anti-IL2R antibody Used for Rheumatoid Arthritis, Psoriasis.
At a glance
| Generic name | Anti-IL2R AB |
|---|---|
| Also known as | daclizumab |
| Sponsor | Astellas Pharma Inc |
| Drug class | Immunomodulator |
| Target | IL2R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Anti-IL2R antibodies are a class of immunomodulatory drugs that target the interleukin-2 receptor (IL2R) to prevent T-cell activation and proliferation.
Approved indications
- Rheumatoid Arthritis
- Psoriasis
Common side effects
- Anemia
- Thrombocytopenia
- Nausea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |